Nexalin Technology NXL
NASDAQ NXL
$2.03 +0.00 (+0.00%)
At close: Oct 22, 2026 · 4:00 PM EDT

Nexalin Technology (NXL) Current Deferred Revenue (2021)

Updated

Nexalin Technology (NXL) recorded Current Deferred Revenue of $130,000 in Q4 2021.

Analysis

Nexalin Technology (NXL) Current Deferred Revenue (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 250.71 Bn 229.74 Bn 4.88 Bn
2 Abbott Laboratories 178.38 Bn 148.81 Bn 7.27 Bn
3 Danaher 161.61 Bn 145.42 Bn 3.61 Bn
4 Intuitive Surgical 154.15 Bn 134.44 Bn 2.08 Bn
5 Medtronic 123.21 Bn 88.46 Bn 6.34 Bn
6 Stryker 117.50 Bn 103.61 Bn 4.50 Bn
7 Boston Scientific 67.50 Bn 62.26 Bn 3.85 Bn
8 Becton Dickinson 54.80 Bn 51.95 Bn 2.32 Bn
9 Edwards Lifesciences 51.78 Bn 35.79 Bn 1.35 Bn
10 Nexalin Technology 1.44 Mn -10.34 Mn 8,897.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 130,000.00
API Access

Nexalin Technology Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=NXL&period=max&api_key=YOUR_API_KEY